Clinical trials
Advanced or Metastatic Solid Tumors clinical trials
Below are recruiting advanced or metastatic solid tumors clinical trials, each written for real people, not researchers. We’re tracking 4,855 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04104776RecruitingPhase 1/Phase 2
Test drug tulmimetostat for advanced cancers and lymphomas
This early-phase study tests tulmimetostat (DZR123) to shrink or control advanced solid tumors and certain lymphomas, and it may also test a combination in some prostate cancer groups. If you qualify, you’ll receive the study drug and be monitored closely, including blood tests and a request for tumor tissue to look for biomarkers.
Tampa, FloridaAges 18 years+ - NCT06799065RecruitingPhase 1
Testing a new drug for advanced solid tumors
This trial tests ATX-295, a daily pill that blocks a protein called KIF18A, in people with advanced solid tumors, including ovarian cancer. It is for those whose cancer has grown after standard treatments or who cannot have standard therapy.
Aurora, ColoradoAges 18 years+ - NCT07704658RecruitingPhase 4
Pralsetinib drug interaction study for advanced solid tumors
This trial tests how pralsetinib interacts with other drugs in people with advanced solid tumors that have a specific RET gene change. It aims to find the right dose and safety profile.
Logroño, La RiojaAges 18 years+ - NCT04762641RecruitingPhase 1
First-dose safety study of ABL503 for advanced cancers
This Phase 1 trial tests the safety and side effects of ABL503 and finds the best dose to study next. It is for people with advanced cancer that is growing despite prior treatment options.
Duarte, CaliforniaAges 18 years+ - NCT06038396RecruitingPhase 1/Phase 2
A study of RC118 plus toripalimab/RC148 for advanced stomach cancer
This trial tests a new drug combination (RC118 plus toripalimab/RC148) for people with advanced stomach or gastroesophageal junction cancer. It’s for those whose cancer has not responded to standard treatment and whose tumors have a specific protein called Claudin 18.2.
Fuzhou, FujianAges 18–75 - NCT06349408RecruitingPhase 1
Testing IBI3001 for advanced solid tumors
This trial tests a new drug called IBI3001 for people with advanced solid tumors that have not responded to other treatments. The goal is to see if it is safe and effective against different types of cancer.
Wollongong, New South WalesAges 18 years+ - NCT05205850RecruitingPhase 1/Phase 2
RC118 for solid cancers with Claudin 18.2 on tumor cells
This Phase 1/2 study tests RC118, a cancer medicine, in people with advanced or spread solid tumors that cannot be removed by surgery. It focuses on tumors that show a specific marker called Claudin 18.2, which may help the treatment work better for some patients.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07205718RecruitingPhase 1/Phase 2
TAK-188 for advanced solid tumors after immunotherapy
This trial tests a new medication called TAK-188 for people with certain advanced solid tumors that have not responded to standard therapies, including checkpoint inhibitors. It aims to see if TAK-188 can help shrink or control the cancer.
Santa Monica, CaliforniaAges 18 years+ - NCT07192120RecruitingPhase 1/Phase 2
MHB048C for advanced solid tumors
This trial is testing a new medicine called MHB048C for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if it can help shrink tumors or slow their growth.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT05205109RecruitingPhase 1
Testing a new melanoma drug alone and with pembrolizumab
This early-stage trial tests ATG 037 to see if it’s safe and how it works in the body, as well as whether it may help people with advanced melanoma. It compares treatment given alone and treatment given together with pembrolizumab, especially in melanoma that has progressed after prior immunotherapy.
Sydney, New South WalesAges 18 years+ - NCT06658353RecruitingPhase 3
Study of VC004 for advanced solid tumors
This trial tests a new drug called VC004 for people with advanced solid tumors that have spread. It aims to see if the drug can shrink tumors or slow their growth.
Beijing, Beijing MunicipalityAges 12 years+ - NCT07469982RecruitingPhase 1
Study of SY-9453 for advanced solid tumors
This trial tests an experimental pill called SY-9453 for people with advanced solid tumors that have a specific genetic change (MTAP deletion). The goal is to see if it is safe and how the body processes it. It may be an option if you have tried standard treatments without success.
ShanghaiAges 18 years+ - NCT06126666RecruitingPhase 1
ABL103 for advanced solid tumors
This trial tests a new drug called ABL103 for people with advanced solid tumors that have not responded to other treatments. The goal is to see if it is safe and effective.
Seongnam, SeoulAges 18 years+ - NCT07646626RecruitingPhase 2
New antibody drugs for advanced HER2-positive cancers
This trial tests two new antibody drugs (SSGJ-705 and SSGJ-612), alone or combined with chemotherapy, in patients with advanced cancers that have a protein called HER2. The study aims to see if this combination can shrink tumors and help patients live longer.
Hangzhou, ZhejiangAges 18–75 - NCT06983743RecruitingPhase 1
ERAS-0015 for Advanced Solid Tumors With RAS Mutations
This trial tests an experimental oral drug called ERAS-0015 for people with advanced solid tumors that have certain genetic changes (RAS mutations). It may be an option if you have no standard treatments left or cannot take them.
Santa Rosa, CaliforniaAges 18–99 - NCT06427941RecruitingPhase 1
Study of BGB-B2033 drug for advanced solid tumors
This trial tests a new drug, BGB-B2033, alone or with other treatments, for people with advanced liver, stomach, lung, or germ cell cancers that have not responded to standard therapy. The goal is to see if the drug is safe and works against these tumors.
Goodyear, ArizonaAges 18 years+ - NCT07066657RecruitingPhase 1
Study of MRG007 for advanced solid tumors
This trial tests a new drug called MRG007 for people with advanced solid tumors that haven't responded to other treatments. The drug targets a protein called CDH17 on cancer cells; you need a tumor sample to check for it.
Los Angeles, CaliforniaAges 18 years+ - NCT04872166RecruitingPhase 1
BTX-A51 for advanced solid tumors and breast cancer patients
This Phase 1 study tests BTX-A51, an experimental treatment, in people with advanced cancers that can’t be cured with standard options. It mainly focuses on safety, side effects, and whether the drug can start helping certain tumors.
Lake Mary, FloridaAges 18 years+ - NCT05076760RecruitingPhase 1
Study of a cancer-killing virus with standard treatments
This Phase 1 trial tests MEM-288, an oncolytic (cancer-killing) virus, either alone or combined with standard cancer medicines, in people with advanced solid tumors. It’s designed to see how the treatment works and how safe it is in different cancer types and after specific prior therapies.
Tampa, FloridaAges 18 years+ - NCT05495295RecruitingPhase 1
First test of PhOx430 for advanced solid tumors
This Phase 1 trial tests a new cancer drug, PhOx430, for people with advanced (metastatic) solid tumors that have not responded to standard treatments. It aims to find a safe dose and to see whether the drug can shrink or control cancer.
MontpellierAges 18–80 - NCT05735080RecruitingPhase 1/Phase 2
INX-315 for advanced cancers with a specific gene change
This trial studies an experimental medicine (INX-315) given in an “open-label” way to people with advanced cancer that has not responded to prior treatment. It mainly looks at safety and side effects first, and also checks how well it works in cancers with a specific gene amplification.
Orlando, FloridaAges 18 years+ - NCT05888532RecruitingPhase 1/Phase 2
Testing a copper-based scan and treatment in advanced cancers
This Phase 1/2 trial studies a copper-labeled medicine called 64Cu-GRIP B in people with advanced, metastatic cancers. It may help doctors see where cancer is and how well the drug works, especially alongside immune checkpoint therapy for some cancer types.
San Francisco, CaliforniaAges 18 years+ - NCT05914545RecruitingPhase 1
Early study drug for advanced solid tumors in adults
This Phase 1 trial tests a new experimental medicine (FZ-AD004) in adults with advanced solid tumors. It aims to see how the drug behaves in the body and whether it’s safe enough to continue in patients with measurable cancer.
ShanghaiAges 18–75 - NCT06107686RecruitingPhase 2
YL202 for advanced solid tumors
This trial tests a new drug called YL202 for people with advanced solid tumors (cancers that have spread or cannot be removed). It aims to see if the drug can shrink tumors or slow cancer growth. You may be able to join if you have certain types of cancer, have not had a previous HER3 treatment, and can provide a tumor sample.
Hefei, AnhuiAges 18–75
Hear when a new Advanced or Metastatic Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for advanced or metastatic solid tumors?
- Yes. Clin2 currently lists 4,855 recruiting advanced or metastatic solid tumors studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a advanced or metastatic solid tumors trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a advanced or metastatic solid tumors trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Locally Advanced or Metastatic Solid Tumors
- Advanced/Metastatic Solid Tumors
- Locally Advanced (Unresectable) or Metastatic Solid Tumors
- Locally Advanced/Metastatic Solid Tumors
- Patients With Advanced Solid Tumors
- Mesothelin-positive Advanced Malignant Solid Tumors
- Recurrent or Metastatic Solid Tumors
- Advanced Solid Tumor
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.